Three Under-the-Radar Small Caps Flying Blind Spots While You Were Watching Oil Headlines

While the financial internet spent last week arguing about Strait of Hormuz headlines and rage-tweeting about gas prices, a few genuinely interesting small-cap stories were accumulating DD with basically zero mainstream coverage. Let's fix that.

$IMVT (Immunovant) is a sub-$5B clinical-stage biotech riding the antibody-drug conjugate wave that CNBC's IBD segment flagged as the hottest platform in global pharma right now. Western giants like Pfizer and AstraZeneca are openly licensing Chinese ADC tech — which means U.S.-listed pure-play ADC biotechs are sitting on potential partnership catalysts that the market hasn't fully priced. Immunovant's FcRn inhibitor pipeline is niche enough that most retail investors couldn't spell it, which is precisely the point. Catalyst: any Phase 2 readout or licensing deal announcement could reprice the stock overnight.

$GESY — wait, that's the Canadian Goeasy that Bloomberg flagged dropping in their Stock Movers segment, which actually makes it interesting: a consumer lending mid-cap getting punished on macro fear despite no fundamental deterioration. Then there's $IIPR (Innovative Industrial Properties), a cannabis-focused REIT that most compliance filters won't touch, keeping institutional ownership artificially low. When sentiment shifts, the re-rating can be violent — in the good way.

The best stocks are always the ones nobody's fighting over yet.